This work is licensed under the Creative Commons Attribution 4.0 International License.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108. 10.3322/caac.21262TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalA.Global cancer statistics, 20122015658710810.3322/caac.21262Open DOISearch in Google Scholar
Fitzmaurice C, Dicker D, Pain A. The global burden of cancer 2013. JAMA Oncol 2015; 1: 505-27. 10.1001/jamaoncol.2015.0735FitzmauriceCDickerDPainA.The global burden of cancer 2013201515052710.1001/jamaoncol.2015.0735Open DOISearch in Google Scholar
Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, et al. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol 2014; 112: 256-61. 10.1016/j.radonc.2014.07.010LiQSwanickCWAllenPKGomezDRWelshJWLiaoZet al.Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications20141122566110.1016/j.radonc.2014.07.010Open DOISearch in Google Scholar
Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005; 63: 1427-31. 10.1016/j.ijrobp.2005.05.034NagataYTakayamaKMatsuoYNorihisaYMizowakiTSakamotoTet al.Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame20056314273110.1016/j.ijrobp.2005.05.034Open DOISearch in Google Scholar
Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 2015; 93: 989-96. 10.1016/j.ijrobp.2015.07.2278NagataYHiraokaMShibataTOnishiHKokuboMKarasawaKet al.Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG04032015939899610.1016/j.ijrobp.2015.07.2278Open DOISearch in Google Scholar
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630-37. 10.1016/S1470-2045(15)70168-3ChangJYSenanSPaulMAMehranRJLouieAVBalterPet al.Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials2015166303710.1016/S1470-2045(15)70168-3Open DOISearch in Google Scholar
Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24: 4833-9. 10.1200/JCO.2006.07.5937TimmermanRMcGarryRYiannoutsosCPapiezLTudorKDeLucaJet al.Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer2006244833910.1200/JCO.2006.07.5937Open DOISearch in Google Scholar
Bush DA, Cheek G, Zaheer S, Wallen J, Mirshahidi H, Katerelos A, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and perIPFheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys 2013; 86: 964-8. 10.1016/j.ijrobp.2013.05.002BushDACheekGZaheerSWallenJMirshahidiHKaterelosAet al.High-dose hypofractionated proton beam radiation therapy is safe and effective for central and perIPFheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center201386964810.1016/j.ijrobp.2013.05.002Open DOISearch in Google Scholar
Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1015-22. 10.1016/j.ijrobp.2010.03.012RegisterSPZhangXMohanRChangJY.Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer20118010152210.1016/j.ijrobp.2010.03.012Open DOISearch in Google Scholar
Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1350-7. 10.1016/j.ijrobp.2010.04.049ChangJYKomakiRWenHYDe GraciaBBluettJBMcAleerMFet al.Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer2011801350710.1016/j.ijrobp.2010.04.049Open DOISearch in Google Scholar
Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 107-111. 10.1016/j.ijrobp.2005.10.031NiheiKOginoTIshikuraSNishimuraH.High-dose proton beam therapy for Stage I non-small-cell lung cancer20066510711110.1016/j.ijrobp.2005.10.031Open DOISearch in Google Scholar
Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall-cell lung cancer. Cancer 2011; 117: 4707-13. 10.1002/cncr.26080ChangJYKomakiRLuCWenHYAllenPKTsaoAet al.Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall-cell lung cancer201111747071310.1002/cncr.26080Open DOISearch in Google Scholar
Kadoya N, Obata Y, Kato T, Kagiya M, Nakamura T, Tomoda T, et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1225-31. 10.1016/j.ijrobp.2010.05.016KadoyaNObataYKatoTKagiyaMNakamuraTTomodaTet al.Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer20117912253110.1016/j.ijrobp.2010.05.016Open DOISearch in Google Scholar
Lee CH, Tait D, Nahum AE, Webb S. Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC). Br J Radiol 1999; 72: 1078-84. 10.1259/bjr.72.863.10700825LeeCHTaitDNahumAEWebbS.Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC)19997210788410.1259/bjr.72.863.10700825Open DOISearch in Google Scholar
Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H. Proton beams to replace photon beams in radical dose treatments. Acta Oncol 2003; 42: 800-8. 10.1080/02841860310017676SuitHGoldbergSNiemierkoATrofimovAAdamsJPaganettiH.Proton beams to replace photon beams in radical dose treatments200342800810.1080/02841860310017676Open DOISearch in Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. 10.1016/j.ejca.2008.10.026EisenhauerEATherassePBogaertsJSchwartzLHSargentDFordRet al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)2009452284710.1016/j.ejca.2008.10.026Open DOISearch in Google Scholar
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82. 10.1016/S0959-8049(99)00229-4YoungHBaumRCremeriusUHerholzKHoekstraOLammertsmaAAet al.Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group19993517738210.1016/S0959-8049(99)00229-4Open DOISearch in Google Scholar
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83. 10.1016/0021-9681(87)90171-8CharlsonMEPompeiPAlesKLMacKenzieCR.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation1987403738310.1016/0021-9681(87)90171-8Open DOISearch in Google Scholar
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6. 10.1016/0360-3016(95)00060-CCoxJDStetzJPajakTF.Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)1995311341610.1016/0360-3016(95)00060-COpen DOISearch in Google Scholar
Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 2009; 66: 89-93. 10.1016/j.lungcan.2008.12.016SongSYChoiWShinSSLeeSWAhnSDKimJHet al.Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus200966899310.1016/j.lungcan.2008.12.016Open DOISearch in Google Scholar
Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014; 90: 1168-76. 10.1016/j.ijrobp.2014.08.008ModhARimnerAWilliamsEFosterAShahMShiWet al.Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy20149011687610.1016/j.ijrobp.2014.08.008Open DOISearch in Google Scholar
Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, von Eyben R, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer 2015; 89: 50-6. 10.1016/j.lungcan.2015.04.014ChaudhuriAATangCBinkleyMSJinMWynneJFvon EybenRet al.Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors20158950610.1016/j.lungcan.2015.04.014Open DOISearch in Google Scholar
Tekatli H, Senan S, Dahele M, Slotman BJ, Verbakel WF. Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. Radiother Oncol 2015; 117: 64-70. 10.1016/j.radonc.2015.09.028TekatliHSenanSDaheleMSlotmanBJVerbakelWF.Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes2015117647010.1016/j.radonc.2015.09.028Open DOISearch in Google Scholar
Mangona VS, Aneese AM, Marina O, Hymas RV, Ionascu D, Robertson JM, et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. Int J Radiat Oncol Biol Phys 2015; 91: 124-32. 10.1016/j.ijrobp.2014.08.345MangonaVSAneeseAMMarinaOHymasRVIonascuDRobertsonJMet al.Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis2015911243210.1016/j.ijrobp.2014.08.345Open DOISearch in Google Scholar
Lischalk JW, Malik RM, Collins SP, Collins BT, Matus IA, Anderson ED, et al. Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases. Radiat Oncol 2016; 11: 28. 10.1186/s13014-016-0608-8LischalkJWMalikRMCollinsSPCollinsBTMatusIAAndersonEDet al.Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases2016112810.1186/s13014-016-0608-8Open DOISearch in Google Scholar
Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2012; 83: e545-9. 10.1016/j.ijrobp.2012.01.018MatsuoYShibuyaKNakamuraMNarabayashiMSakanakaKUekiNet al.Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer201283e545910.1016/j.ijrobp.2012.01.018Open DOISearch in Google Scholar
Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012; 82: 457-62. 10.1016/j.ijrobp.2010.08.056BarrigerRBForquerJABrabhamJGAndolinoDLShapiroRHHendersonMAet al.A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy2012824576210.1016/j.ijrobp.2010.08.056Open DOISearch in Google Scholar
Nakayama H, Sugahara S, Tokita M, Satoh H, Tsuboi K, Ishikawa S, et al. Proton beam therapy for patients with medically inoperable stage I nonsmall-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys 2010; 78: 467-71. 10.1016/j.ijrobp.2009.07.1707NakayamaHSugaharaSTokitaMSatohHTsuboiKIshikawaSet al.Proton beam therapy for patients with medically inoperable stage I nonsmall-cell lung cancer at the university of tsukuba2010784677110.1016/j.ijrobp.2009.07.1707Open DOISearch in Google Scholar
Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ 2016; 354: i3570. 10.1136/bmj.i3570PaulSLeePCMaoJIsaacsAJSedrakyanA.Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis2016354i357010.1136/bmj.i3570Open DOISearch in Google Scholar